RVX-sCPD9
Phase 1
RVX-sCPD9 is one of 13 therapeutic programs targeting COVID-19. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
311 competitors in COVID-19
#DrugCompanyPhaseTrials
1RVX-sCPD9
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
Other Tkis
BayerPreclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
Pfizer-Biontech COVID-19 MRNA Vaccine
PfizerPreclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Tpa
UUniversity of Florida
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
SARS-Cov-2 Bivalent MRNA Vaccine
AAIM Vaccine Co., Ltd.
Preclinical
Serological Test
CCentre Hospitalier de Cornouaille
Preclinical
Exebacase
CContraFect
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-191 trial
A Phase 1, Open-Label, Safety, Reactogenicity, and Immunogenicity Trial of RVX-sCPD9, a Live-Attenuated SARS-CoV-2, as a Booster Vaccine, Via the Intranasal Route in Previously Vaccinated Adults
Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07703475·80 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for RVX-sCPD9. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]